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Even when patients with nonsmall cell lung cancer undergo surgical resection at an early stage, recurrent disease often impairs
the clinical outcome. There are numerous causes potentially responsible for a relapse of the disease, one of them being extensive
angiogenesis. The balance of at least two systems, VEGF VEGFR and Ang Tie, regulates vessel formation. The aim of this study
was to determine the impact of surgery on the plasma levels of the main angiogenic factors during the ﬁrst month after surgery
in nonsmall cell lung cancer patients. The study group consisted of 37 patients with stage I nonsmall cell lung cancer. Plasma
concentrations of Ang1, Ang2, sTie2, VEGF, and sVEGF R1 were evaluated by ELISA three times: before surgical resection and on
postoperative days 7 and 30. The median of Ang2 and VEGF concentrations increased on postoperative day 7 and decreased on
day 30. On the other hand, the concentration of sTie2 decreased on the 7th day after resection and did not change statistically later
on. The concentrations of Ang1 and sVEGF R1 did not change after the surgery. Lung cancer resection results in proangiogenic
plasma protein changes that may stimulate tumor recurrences and metastases after early resection.
1.Introduction
Surgical resection remains the standard treatment for pa-
tients with stage I nonsmall cell lung cancer (NSCLC). Even
inpatientswhoundergosurgicalresectionatanearlystageof
NSCLC,recurrentdiseaseoftenimpairstheclinicaloutcome.
The postoperative 5-year survival rate for stage IA and IB
NSCLC was reported to range from 72% to 46% in America
a n di nE u r o p e a nc o u n t r i e s[ 1, 2].
The major cause of death among cancer patients
is angiogenesis-mediated progression of micrometastases
(<1mm in diameter) to lethal macrometastases (≥1mm)
[3]. Recent ﬁndings suggest that the critical regulators of
the angiogenic switch are bone-marrow-derived endothelial
progenitor cells (EPCs) [3]. The soluble factors (e.g., VEGF)
secreted by tumors promote the release of both bone-
marrow-derived EPCs (including CD34+ VEGFR2+ cells)
and hematopoietic cells (including Tie2 expressing mono-
cytes, CXCR4+VEGFR1+ hemangiocytes) into the periph-
eral circulation and their recruiting to primary tumor or
metastatic lesions [4]. The level of circulating bone marrow-
derived EPCs is signiﬁcantly increased in NSCLC patients2 ISRN Oncology
and correlated with the clinical situation [5, 6]. EPCs con-
tributetoneovascularizationbydirectluminalincorporation
into sprouting nascent vessels [7] and via paracrine secretion
of proangiogenic growth factors [8].
The balance of at least two systems, VEGF-VEGFR
and Ang-Tie, regulates vessel formation. VEGF is a potent
mitogen for micro- and macrovascular endothelial cells
derived from arteries, veins, and lymphatics. It directly
induces endothelial cell proliferation, migration, and tube
formation. The biological eﬀects of VEGF are mediated by
two tyrosine kinase receptors, Flt1 (VEGF R1) and KDR
(VEGF R2) [9, 10]. Alternative splicing of these mRNA
receptors results in soluble forms of each receptor [11].
The soluble form of VEGF R1 (sVEGF R1) inhibits VEGF
activity by sequestering VEGF from signaling receptors and
by forming nonsignaling heterodimers with VEGF R2 [12].
Ang1 and Ang2 act through competitive binding to
the extracellular domain of the endothelial cell—speciﬁc
receptortyrosinekinaseTie2.WhileAng1isanagonist,Ang2
could act as an antagonist or agonist depending on cell type
and microenvironmental conditions. Several cell types in
various tissues express Ang1. Ang2 is mainly expressed in
endothelial cells located at sites of vascular remodeling, and
it is stored in intracellular WeibelPalade bodies. Ang2 desta-
bilizes capillary integrity by the disruption of connections
betweentheendotheliumandtheperivascularcellsandalone
promotescelldeathandvesselregression,but,inconjunction
with VEGF, it promotes neovascularization. Ang1 mediates
migration, adhesion and survival of endothelial cells—it can
elicit an antiapoptotic eﬀect. Generally, it has stabilizing
eﬀects on blood vessels and anti-inﬂammatory properties
and acts as a sealing-up factor [13, 14]. According to recent
ﬁndings (2010) [15], the Ang1/Tie2 signal regulates not
only vascular quiescence but also angiogenesis. Downstream
signaling of Ang1/Tie2 is dependent on the presence or
absence of cell-cell contacts. When cell-cell adhesions are
disrupted by VEGF, Ang1 induces the formation of ECM-
anchored Tie2 and accelerates angiogenesis cooperatively
with VEGF. Soluble Tie2 (sTie2), diﬀerently from sVEGF R1,
is released from Tie2-expressing ECs by a yet unidentiﬁed
mechanism. Several factors may inﬂuence this shedding
process. sTie2 is not capable of signal transduction, but by
binding to free Ang1 and Ang2 in the plasma it modulates
the impact of these factors on angiogenesis [16].
Clinical studies have demonstrated that surgery is asso-
ciated with changes in plasma composition that make the
patient more susceptible to tumor recurrence [17, 18].
Among plasma proteins whose concentrations are altered
after surgery are angiogenic factors.
The aim of this study was to determine the impact of
surgery on the plasma levels of the main angiogenic factors
during the ﬁrst month after surgery in non-small cell lung
cancer patients.
2.MaterialsandMethods
2.1.StudyPopulation. Thestudyincludedpatientswithstage
Io fn o n - s m a l lc e l ll u n gc a n c e r ,w h ou n d e r w e n tt u m o rr e s e c -
tion without any preoperative therapy. These patients were
treated in the University Hospital Department of Thoracic
Surgery and Tumors, Collegium Medicum in Bydgoszcz,
Nicolaus Copernicus University in Toru´ n, during the years
2008–2010. Three blood samples were taken from each
patient: one prior to surgery and others on postoperative
days 7 and 30.
The experiment was conducted with the understanding
and the consent of the human subject. The study protocol
was approved by the Ethical Committee of the Collegium
Medicum in Bydgoszcz, Nicolaus Copernicus University in
Toru ´ n (Poland).
2.2. Blood Sampling and Processing. Ang1, Ang2, sTie2,
VEGF, sVEGF R1 concentrations were evaluated in plasma.
Four millilitres of blood were taken from elbow vein. EDTA
was used as an anticoagulant. Within 30 minutes after the
collection, the blood samples were centrifuged at 2–8◦Cf o r
15 minutes at 1000 × g. For complete platelet removal,
an additional centrifuge at 10,000 × gf o r1 0m i n u t e sw a s
applied. The plasma was stored at −70◦C.
2.3. Angiogenic Factors Determinations. Ang1, Ang2, sTie2,
VEGF, sVEGF R1 concentrations were assayed by com-
merciallyavailablesandwichenzyme-linkedimmunosorbent
assay kits from R&D Systems (Quantikine Human Ang1,
Ang2, sTie2, VEGF, sVEGF R1 Immunoassay, R&D Systems
Inc., Minneapolis, USA). Kits are designed to measure
h u m a nA n g 1 ,A n g 2 ,s T i e 2 ,V E G F ,s V E G FR 1i nc e l lc u l t u r e
supernates, serum, plasma, and other biological ﬂuids.
Plasma samples for detection of these ﬁve factors were
diluted 15-, 5-, 10-, 1-, 10-folded, respectively.
2.4. Statistical Analysis. Statistical analysis was done using
nonparametric Mann-Whitney’s test, Wilcoxon signed-rank
test, and Pearson’s linear correlation. The results were con-
sidered statistically signiﬁcant for P<0.05.
3. Results
The study group consisted of 37 patients with non-small
cell lung cancer (10 females and 27 males) aged 42 to 80
( w i t ha na v e r a g ea g eo f6 4 .7 ± 9.0). By the standards of
clinical staging, all patients were classiﬁed as stage I (IA-9,
IB-28). Twenty-ﬁve patients had squamous cell carcinoma,
6-adenocarcinoma and 6-other histological types of tumor
(large cell anaplastic and neuroendocrine carcinoma). The
most frequent histological grade was G2 (moderately diﬀer-
entiated).
Table 1 presents concentrations of Ang1, Ang2, sTie2,
VEGF, and sVEGF R1 before the surgical treatment of
lung cancer patients as well as on the 7th and 30th days
after tumor resection. The concentration of Ang1 did not
signiﬁcantly change after resection. The median of Ang2
concentration increased on the 7th day (3688.70 versus
2501.30pg/mL; P<0.0001) and subsequently decreased
on the 30th day (2858.25 versus 3688.70pg/mL; P<0.01),
but it was still elevated in comparison to the pretreatment
state (2858.25 versus 2501.30pg/mL; P<0.05). ChangesISRN Oncology 3
Table 1: Theplasma concentration of Ang1, Ang2, sTie2, VEGF, and sVEGF R1 in controls and lungcancer patients before and after surgical
treatment (median, 25–75 percentile).
Controls
Lung cancer
Before After 7 After 30 P value
Median Median Median Median
(25–75 percentile) (25–75 percentile) (25–75 percentile) (25–75 percentile)
Ang1 [pg/mL] 976.7
(0.0–2094.5)
5682.0
(3118.9–8939.4)
7496.6
(3266.0–11100.0)
5279.1
(990.7–8054.1)
Ang2 [pg/mL] 1668.3
(1291.4–2139.7)
2501.3
(2138.7–2645.4)
3688.7
(2414.1–4841.70)
2858.2
(2177.2–3502.6)
∗P<0.0001
∗∗P<0.01
∗∗∗P<0.05
sTie2 [pg/mL] 15788
(11975–30534)
24806
(16545–28939)
22567
(16859–26375)
25 318
(21584–33965)
∗P<0.05
VEGF [pg/mL] 66.1
(38.6–99.4)
124.4
(66.6–251.5)
238.5
(113.3–521.6)
115.5
(42.9–91.0)
∗P<0.01
sVEGF-R1 [pg/mL] 107.8
(86.1–122.9)
95.9
(83.7–120.8)
94.7
(83.0–113.3)
95.9
(88.4–121.6)
Before: before surgical treatment; After 7: on day 7 after treatment; After 30: on day 30 after treatment.
∗Before versus after 7; ∗∗after 7 versus after 30; ∗∗∗before versus after 30.
in VEGF concentration were similar to those observed for
Ang2; the median of VEGF increased on the 7th day (238.50
versus 124.40pg/mL; P<0.01). However, the concentration
of sTie2 decreased on the 7th day after resection (22,567.0
versus 24,806.0pg/mL; P<0.05) and did not change
statistically later on. The concentration of sVEGF R1 did not
change after resection.
Inthisstudy,factorcorrelationswereestimated(Table 2).
The correlation of Ang1 and Ang2 was weak, both positive
and negative, at all observation points (before: r = 0.34;
after 7: r =− 0.20; after 30: r = 0.15). The correlation
between Ang1 and sTie2 was weak and constant (r = 0.11;
r = 0.07; r = 0.21); on the other hand, the correlation
between Ang2 and sTie2 was repeatedly strong, from slightly
negative to highly positive (r =− 0.04; r = 0.32; r = 0.63).
Correlation coeﬃcients for dependence between Ang1 and
VEGF were high (r = 0.49; r = 0.54; r = 0.6 4 ) ;h o w e v e r ,f o r
Ang2 and VEGF were from moderately positive to slightly
negative (r = 0.39; r = 0.10; r =− 0.01). The correlations
between VEGF and sVEGF R1 as well sTie2 and sVEGF R1
were moderate.
4. Discussion
Manypatientswithsolidtumorswhoundergosurgicalresec-
tion develop local recurrences and remote metastases from
residual tumor cells postoperatively. There are numerous
causes potentially responsible for a relapse of the disease, one
of them being extensive angiogenesis.
Although the postoperative angiogenesis response is
well established after surgery, the exact causes and sources
of angiogenic factors remain unclear. It is proposed that
surgery-induced hypoxia, metabolic changes, and inﬂam-
mation are the three major causes of the production of
angiogenic factors in cancer cells as well as in normal cells
(e.g., immune cells and ﬁbroblasts) [19]. Upon surgery,
hypoxia-inducible factor (HIF) induces the expression of
downstream angiogenic factors such as VEGF and Ang2 in
residual cancer cells [20]. An HIF-independent angiogenesis
pathway is mainly mediated by the transcriptional coacti-
vator PGC-1 α (peroxisome-proliferator-activated receptor-
gamma coactivator-1-α). It is a potent metabolic sensor and
regulator induced by a lack of nutrients and oxygen, and it
powerfully regulates VEGF expression and angiogenesis in
cultured muscle cells and in skeletal muscle in vivo [21].
Surgery-related inﬂammation is another crucial contributor
to angiogenic response following surgical tumor resection.
The inﬁltrating macrophages, immature dendritic cells, and
carcinoma-activated ﬁbroblasts are recruited to the surgical
site and release numerous angiogenic factors [22].
The aim of this study was to determine the impact of
surgery on the plasma levels of the main angiogenic factors
duringtheﬁrstmonthaftersurgery.VEGFisthemostpotent
promoter of angiogenesis. Ang2 supports VEGF proangio-
genic eﬀects. Ang1 stabilizes mature blood vessels. Soluble
Tie2 modulates the impact of both proteins on angiogenesis
by binding free Ang1 and Ang2 in the bloodstream. VEGFR1
binds VEGF and limits the proangiogenic eﬀects of VEGF at
the level of endothelial cells [9–16].
We found that lung cancer surgery is associated with
signiﬁcantlyincreasedplasmaVEGFandAng2levelspostop-
eratively. VEGF was increased for at least 7 days, Ang2 for 30
d a y s ;h o w e v e r ,s T i e 2w a sd e c r e a s e d .A l lo ft h e s ec h a n g e sa r e
proangiogenic. Plasma Ang1 and sVEGFR1 concentrations
did not change signiﬁcantly in the postoperative period.
Although Ang1 levels did not change and Ang2 increased,
the Ang1/Ang2 ratio remained unchanged, but there was
at e n d e n c yf o ru n f a v o r a b l ed e c r e a s e .T h eA n g 1 / A n g 2r a t i o
may be more important than angiopoietin levels and it
depends on the angiogenic phase; when Ang2 expression is
relatively higher than that of Ang1, the induction of tumor
angiogenesis is triggered (the “angiogenic switch” is turned
on).4 ISRN Oncology
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Postoperatively increased plasma concentrations of
VEGF and Ang2 should be considered in conjunction with
those of their inhibitors: sVEGFR1 and sTie2, respectively.
The lack of change in sVEGF R1 and a decrease in total
sTie2 blood concentration after surgery should result in a
greater amount of VEGF and Ang2 free to bind to EC-bound
receptors. The VEGF/sVEGFR1 and Ang2/sTie2 ratios were
greater both on postoperative days 7 and 30 than the
preoperative baseline, and the eﬀective concentrations of
VEGF and Ang2 were increased after surgery.
In our study, a correlation between Ang2 and VEGF
before surgery was noted (r = 0.39). A higher correlation
was found between Ang1 and VEGF, both before surgery
(r = 0.49) and on postoperative days 7 (r = 0.54) and 30
(r = 0.64).
The problem concerning NSCLC resection has not been
addressed in published studies (according to our searches),
although Kumara et al. [23–25] investigated this issue in
colorectal cancer. We obtained results similar to theirs.
As colorectal resection is associated with persistent proan-
giogenic plasma protein changes (increase of VEGF and
Ang2 levels), Shantha Kumara et al. [26] assessed the
impact of preoperative and postoperative plasma on in vitro
endothelial cell behavior. Postoperative plasma stimulates in
vitro endothelial cell growth, migration and invasion, so it
may stimulate the growth of residual tumor.
Elevated plasma VEGF levels could have an impact on
tumor recurrence, growth of micrometastases, or develop-
ment of new metastases in the early postoperative period.
There are some good reasons to believe that (1) VEGF is
a critical cytokine in tumor angiogenesis and a target for
therapy[27],(2)tumorgrowthisintensiﬁedbyVEGF,which
binds to endothelial cells and initiates the process of new
blood vessel formation [28], (3) high preoperative blood
VEGF levels are associated with more advanced disease and a
worse prognosis in lung cancer patients [29, 30].
Similarly to VEGF, an increased plasma Ang2 concen-
tration may contribute to angiogenesis-mediated relapse of
the disease due to the following facts: (1) Ang2 destabilizes
capillary integrity and, in conjunction with VEGF, promotes
neovascularization [31]a sw e l la st u m o ra n g i o g e n e s i s[ 32];
(2) increased plasma/serum concentration of Ang2 was
observed in various cancers, among others in lung cancer
[33], breast and prostate cancer [34], and cervical cancer
[35]; (3) in many studies the correlation between Ang2
expression and tumor progression was observed [36–39]; (4)
theexpression/concentration ofAng2 correlateswithvarious
angiogenesis factors, for example, with VEGF in liver cancer
[39], which suggests their synergistic role in the regulation of
tumor angiogenesis.
5. Conclusions
All the presented data seem to suggest that proangiogenic
plasma alterations after surgery may result in cancer patients
developing recurrent disease either from unrecognized tissue
microfoci of tumor cells or from viable cells that persist
in the circulation. The inclusion of angiogenic factors in
the postoperative diagnostics of lung cancer could lead to
improved follow-up therapy and individual antiangiogenic
therapy.
Conﬂict of Interests
The authors declare that they have no conﬂict of interests.
Acknowledgment
The research was supported by the grant of Nicolaus Co-
pernicus University in Toru´ n, no. 21/2010.
References
[ 1 ]M .T .M .V a nR e n s ,A .B r u t e ld el aR i v i ` ere, H. R. J. Elbers,
and J. M. M. Van den Bosch, “Prognostic assessment of 2,361
patients who underwent pulmonary resection for non-small
cell lung cancer, stage I, II, and IIIA,” Chest, vol. 117, no. 2, pp.
374–379, 2000.
[2] D. Fang, D. Zhang, G. Huang, R. Zhang, L. Wang, and D.
Zhang, “Results of surgical resection of patients with primary
lung cancer: a retrospective analysis of 1,905 cases,” Annals of
Thoracic Surgery, vol. 72, no. 4, pp. 1155–1159, 2001.
[3] D. Gao, D. J. Nolan, A. S. Mellick, K. Bambino, K. McDonnell,
and V. Mittal, “Endothelial progenitor cells control the
angiogenic switch in mouse lung metastasis,” Science, vol. 319,
no. 5860, pp. 195–198, 2008.
[4] D. Gao, D. Nolan, K. McDonnell et al., “Bone marrow-
derived endothelial progenitor cells contribute to the angio-
genic switch in tumor growth and metastatic progression,”
BiochimicaetBiophysicaActa,vol.1796,no.1,pp.33–40,2009.
[5] K. Nowak, N. Rafat, S. Belle et al., “Circulating endothelial
progenitor cells are increased in human lung cancer and
correlate with stage of disease,” European Journal of Cardio-
Thoracic Surgery, vol. 37, no. 4, pp. 758–763, 2010.
[6] B. Dome, J. Timar, J. Dobos et al., “Identiﬁcation and
clinical signiﬁcance of circulating endothelial progenitor cells
inhumannon-smallcelllungcancer,”CancerResearch,vol.66,
no. 14, pp. 7341–7347, 2006.
[7] W. Hilbe, S. Dirnhofer, F. Oberwasserlechner et al., “CD133
positive endothelial progenitor cells contribute to the tumour
vasculature in non-small cell lung cancer,” Journal of Clinical
Pathology, vol. 57, no. 9, pp. 965–969, 2004.
[8] C. H. Yoon, J. Hur, K. W. Park et al., “Synergistic neovas-
cularization by mixed transplantation of early endothelial
progenitor cells and late outgrowth endothelial cells: The
role of angiogenic cytokines and matrix metalloproteinases,”
Circulation, vol. 112, no. 11, pp. 1618–1627, 2005.
[9] N. Ferrara, “Role of vascular endothelial growth factor in reg-
ulation of physiological angiogenesis,” American Journal of
Physiology, vol. 280, no. 6, pp. C1358–C1366, 2001.
[10] H. Takahashi and M. Shibuya, “The vascular endothelial
growth factor (VEGF)/VEGF receptor system and its role
under physiological and pathological conditions,” Clinical
Science, vol. 109, no. 3, pp. 227–241, 2005.
[11] C. J. Robinson and S. E. Stringer, “The splice variants of vas-
cular endothelial growth factor (VEGF) and their receptors,”
Journal of Cell Science, vol. 114, no. 5, pp. 853–865, 2001.
[12] F. T. H. Wu, M. O. Stefanini, F. M. Gabhann, C. D. Kontos,
B .H .A n n e x ,a n dA .S .P o p e l ,“ As y s t e m sb i o l o g yp e r s p e c t i v e
on sVEGFR1: its biological function, pathogenic role and6 ISRN Oncology
therapeutic use,” Journal of Cellular and Molecular Medicine,
vol. 14, no. 3, pp. 528–552, 2010.
[13] L. Eklund and B. R. Olsen, “Tie receptors and their angiopoi-
etin ligands are context-dependent regulators of vascular
remodeling,” Experimental Cell Research, vol. 312, no. 5, pp.
630–641, 2006.
[14] N. P. J. Brindle, P. Saharinen, and K. Alitalo, “Signaling and
functions of angiopoietin-1 in vascular protection,” Circula-
tion Research, vol. 98, no. 8, pp. 1014–1023, 2006.
[15] S. Fukuhara, K. Sako, K. Noda, J. Zhang, M. Minami,
and N. Mochizuki, “Angiopoietin-1/Tie2 receptor signaling
in vascular quiescence and angiogenesis,” Histology and
Histopathology, vol. 25, no. 3, pp. 387–396, 2010.
[16] P. Reusch, B. Barleon, K. Weindel et al., “Identiﬁcation of a
soluble form of the angiopoietin receptor TIE-2 released from
endothelial cells and present in human blood,” Angiogenesis,
vol. 4, no. 2, pp. 123–131, 2001.
[17] Y. Hu, B. Li, G. Shi, C. Rong, and G. Gao, “Correlation of
postoperative serum VEGF levels with platelet counts in non-
small cell lung cancer,” Chinese Journal of Lung Cancer, vol. 13,
no. 2, pp. 118–121, 2010.
[18] Y. Hu, B. Li, and C. Song, “Clinical research of perioperative
serumVEGFandMMP-9levelsinpatientswithnon-smallcell
lung cancer,” Chinese Journal of Lung Cancer,v o l .1 1 ,n o .5 ,p p .
734–738, 2008.
[ 1 9 ]B .K o n g ,C .W .M i c h a l s k i ,H .F r i e s s ,a n dJ .K l e e ﬀ,“ S u r g i c a l
procedure as an inducer of tumor angiogenesis,” Experimental
Oncology, vol. 32, no. 3, pp. 186–189, 2010.
[20] J. Pouyss´ egur, F. Dayan, and N. M. Mazure, “Hypoxia
signalling in cancer and approaches to enforce tumour
regression,” Nature, vol. 441, no. 7092, pp. 437–443, 2006.
[21] Z. Arany, S. Y. Foo, Y. Ma et al., “HIF-independent regulation
of VEGF and angiogenesis by the transcriptional coactivator
PGC-1α,” Nature, vol. 451, no. 7181, pp. 1008–1012, 2008.
[22] P. Carmeliet, “Angiogenesis in life, disease and medicine,”
Nature, vol. 438, no. 7070, pp. 932–936, 2005.
[23] A. Belizon, E. Balik, P. Horst et al., “Persistent elevation
of plasma vascular endothelial growth factor levels during
the ﬁrst month after minimally invasive colorectal resection,”
Surgical Endoscopy and Other Interventional Techniques, vol.
22, no. 2, pp. 287–297, 2008.
[24] H. M. C. Shantha Kumara, J. C. Cabot, A. Hoﬀman et al.,
“Minimally invasive colon resection is associated with a
transient increase in plasma sVEGFR1 levels and a decrease
in sVEGFR2 levels during the early postoperative period,”
Surgical Endoscopy and Other Interventional Techniques, vol.
23, no. 4, pp. 694–699, 2009.
[25] H. M. C. Shantha Kumara, M. J. Grieco, X. Yan et al., “Min-
imally invasive colorectal resection for cancer is associated
with a short-lived decrease in soluble Tie-2 receptor levels,
which may transiently inhibit VEGF-mediated angiogenesis
(via altered blood levels of free Ang-1 and Ang-2),” Surgical
Endoscopy and Other Interventional Techniques, vol. 24, no. 10,
pp. 2581–2587, 2010.
[26] H. M. C. Shantha Kumara, D. Feingold, M. Kalady et al., “Col-
orectal resection is associated with persistent proangiogenic
plasma protein changes: Postoperative plasma stimulates in
vitro endothelial cell growth, migration, and invasion,” Annals
of Surgery, vol. 249, no. 6, pp. 973–977, 2009.
[27] H. F. Dvorak, “Vascular permeability factor/vascular endothe-
lial growth factor: A critical cytokine in tumor angiogenesis
and a potential target for diagnosis and therapy,” Journal of
Clinical Oncology, vol. 20, no. 21, pp. 4368–4380, 2002.
[28] Y.Ito,H.Hasuda,H.Terai,andT.Kitajima,“Cultureofhuman
umbilical vein endothelial cells on immobilized vascular
endothelial growth factor,” Journal of Biomedical Materials
Research Part A, vol. 74, no. 4, pp. 659–665, 2005.
[29] J. Trap´ e, J. Bux´ o, and J. P. De Olaguer, “Serum concentrations
of vascular endothelial growth factor in advanced non-small
cell lung cancer,” Clinical Chemistry, vol. 49, no. 3, pp. 523–
525, 2003.
[30] Y. Shimanuki, K. Takahashi, R. Cui et al., “Role of serum
vascular endothelial growth factor in the prediction of angio-
genesis and prognosis for non-small cell lung cancer,” Lung,
vol. 183, no. 1, pp. 29–42, 2005.
[31] T.Asahara,D.Chen,T.Takahashietal.,“Tie2receptorligands,
angiopoietin-1 and angiopoietin-2, modulate VEGF- induced
postnatal neovascularization,” Circulation Research, vol. 83,
no. 3, pp. 233–240, 1998.
[32] J. Holash, P. C. Maisonpierre, D. Compton et al., “Vessel
cooption, regression, and growth in tumors mediated by
angiopoietins and VEGF,” Science, vol. 284, no. 5422, pp.
1994–1998, 1999.
[33] H. P. Joo, J. P. Kwang, S. K. Young et al., “Serum angiopoietin-
2 as a clinical marker for lung cancer,” Chest, vol. 132, no. 1,
pp. 200–206, 2007.
[34] G. J. Caine, A. D. Blann, P. S. Stonelake, P. Ryan, and G. Y.
H. Lip, “Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in
breast and prostate cancer: A comparison with VEGF and Flt-
1,” European Journal of Clinical Investigation, vol. 33, no. 10,
pp. 883–890, 2003.
[35] E.Kopczy´ nska,R.Makarewicz,M.Biedka,A.Kaczmarczyk,H.
Kardymowicz, and T. Tyrakowski, “Plasma concentration of
angiopoietin-1, angiopoietin-2 and Tie-2 in cervical cancer,”
EuropeanJournalofGynaecologicalOncology,vol.30,no.6,pp.
646–649, 2009.
[36] A. Eggert, N. Ikegaki, J. Kwiatkowski, H. Zhao, G. M. Brodeur,
and B. P. Himelstein, “High-level expression of angiogenic
factors is associated with advanced tumor stage in human
neuroblastomas,” Clinical Cancer Research,v o l .6 ,n o .5 ,p p .
1900–1908, 2000.
[37] Y. Reiss, M. R. Machein, and K. H. Plate, “The role of
angiopoietins during angiogenesis in gliomas,” Brain Pathol-
ogy, vol. 15, no. 4, pp. 311–317, 2005.
[38] T. Nakayama, G. Hatachi, C. Y. Wen et al., “Expression and
signiﬁcance of Tie-1 and Tie-2 receptors, and angiopoietins-1,
2 and 4 in colorectal adenocarcinoma: Immunohistochemical
analysis and correlation with clinicopathological factors,”
World Journal of Gastroenterology, vol. 11, no. 7, pp. 964–969,
2005.
[39] W. S. Moon, K. H. Rhyu, M. J. Kang et al., “Overexpression
of VEGF and angiopoietin 2: A key to high vascularity of
hepatocellular carcinoma?” Modern Pathology, vol. 16, no. 6,
pp. 552–557, 2003.